Lipocine Operating Margin from 2010 to 2026
| LPCN Stock | USD 8.81 0.08 0.90% |
Check Lipocine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lipocine's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 5.8 M or Total Revenue of 13.5 M, as well as many indicators such as Price To Sales Ratio of 2.54, Dividend Yield of 0.0 or PTB Ratio of 1.17. Lipocine financial statements analysis is a perfect complement when working with Lipocine Valuation or Volatility modules.
Lipocine | Operating Margin | Build AI portfolio with Lipocine Stock |
Evaluating Lipocine's Operating Margin across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Lipocine's fundamental strength.
Latest Lipocine's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Lipocine over the last few years. It is Lipocine's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lipocine's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (29.34) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Lipocine Operating Margin Regression Statistics
| Arithmetic Mean | (14.90) | |
| Coefficient Of Variation | (142.06) | |
| Mean Deviation | 16.70 | |
| Median | (0.10) | |
| Standard Deviation | 21.17 | |
| Sample Variance | 448.02 | |
| Range | 84.4781 | |
| R-Value | 0.14 | |
| Mean Square Error | 468.35 | |
| R-Squared | 0.02 | |
| Significance | 0.59 | |
| Slope | 0.59 | |
| Total Sum of Squares | 7,168 |
Lipocine Operating Margin History
About Lipocine Financial Statements
Lipocine investors utilize fundamental indicators, such as Operating Margin, to predict how Lipocine Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The companys pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression LPCN 2101 for women with epilepsy, which has completed pre-clinical study and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth
Pair Trading with Lipocine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipocine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipocine will appreciate offsetting losses from the drop in the long position's value.Moving together with Lipocine Stock
| 0.72 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Lipocine Stock
| 0.9 | HPQ | HP Inc Aggressive Push | PairCorr |
| 0.62 | MSFT | Microsoft Sell-off Trend | PairCorr |
| 0.59 | BRK-A | Berkshire Hathaway | PairCorr |
| 0.48 | VLCN | Volcon Inc Symbol Change | PairCorr |
| 0.37 | IBM | International Business | PairCorr |
The ability to find closely correlated positions to Lipocine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipocine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipocine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipocine to buy it.
The correlation of Lipocine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipocine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipocine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipocine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Lipocine Correlation against competitors. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Will Pharmaceuticals sector continue expanding? Could Lipocine diversify its offerings? Factors like these will boost the valuation of Lipocine. Expected growth trajectory for Lipocine significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lipocine data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.02) | Revenue Per Share | Quarterly Revenue Growth 5.954 | Return On Assets | Return On Equity |
Understanding Lipocine requires distinguishing between market price and book value, where the latter reflects Lipocine's accounting equity. The concept of intrinsic value - what Lipocine's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Lipocine's price substantially above or below its fundamental value.
Understanding that Lipocine's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lipocine represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Lipocine's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.